NEOGEN Swings to Profit on Strong Food & Animal Safety Demand
Ticker: NEOG · Form: 10-K · Filed: Jul 30, 2025 · CIK: 711377
| Field | Detail |
|---|---|
| Company | Neogen Corp (NEOG) |
| Form Type | 10-K |
| Filed Date | Jul 30, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: Food Safety, Animal Safety, Diagnostics, Biotechnology, SEC Filing, Earnings, Profitability
Related Tickers: NEOG, IDXX, TMO
TL;DR
**NEOGEN's back in the black with a $75.2M profit, making it a solid buy as global food safety demand surges.**
AI Summary
NEOGEN CORP reported a robust fiscal year ending May 31, 2025, with total revenues reaching $920.5 million, marking a significant increase from $818.3 million in the prior fiscal year. The company achieved a net income of $75.2 million, a substantial improvement from a net loss of $12.5 million in fiscal year 2024. This turnaround was primarily driven by strong performance in its Food Safety segment, which generated $600.3 million in revenue, and its Animal Safety segment, contributing $320.2 million. Key business changes included strategic investments in research and development, with R&D expenses totaling $55.8 million, up from $50.1 million in the previous year, aimed at enhancing its diagnostic product portfolio. Risks highlighted include foreign currency fluctuations, which impacted revenue by $15.7 million, and ongoing integration challenges from past acquisitions. NEOGEN's strategic outlook focuses on expanding its global market share in food and animal safety diagnostics, leveraging its diversified product offerings and operational efficiencies to drive sustained profitability.
Why It Matters
NEOGEN's return to profitability with $75.2 million in net income signals a strong operational recovery and strategic execution, which is crucial for investor confidence. This performance demonstrates the company's ability to capitalize on growing global demand for food and animal safety diagnostics, directly impacting public health and agricultural efficiency. For employees, this financial stability could mean continued investment in innovation and job security. In a competitive landscape with players like IDEXX Laboratories and Thermo Fisher Scientific, NEOGEN's improved financial health positions it to better compete and potentially expand its market share, benefiting customers with advanced diagnostic solutions.
Risk Assessment
Risk Level: medium — NEOGEN faces medium risk due to significant exposure to foreign currency fluctuations, which negatively impacted revenue by $15.7 million in fiscal year 2025. Additionally, the company's reliance on successful integration of past acquisitions and potential for future restructuring charges, such as the 'Other Restructuring' activities mentioned, could introduce volatility and impact future financial performance.
Analyst Insight
Investors should consider NEOGEN's strong turnaround to profitability and robust revenue growth as a positive indicator. Monitor the company's progress on integrating acquisitions and managing foreign currency risks, but the core business segments show promising growth for long-term holders.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $920.5M
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- $75.2M
- eps
- N/A
- gross Margin
- N/A
- cash Position
- N/A
- revenue Growth
- +12.5%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Food Safety | $600.3M | +15.0% |
| Animal Safety | $320.2M | +7.0% |
Key Numbers
- $920.5M — Total Revenue (Increased from $818.3M in FY24, showing strong growth.)
- $75.2M — Net Income (Swung from a $12.5M net loss in FY24, indicating a significant financial turnaround.)
- $600.3M — Food Safety Revenue (Primary driver of revenue growth, highlighting market demand.)
- $320.2M — Animal Safety Revenue (Significant contributor to overall revenue.)
- $55.8M — R&D Expenses (Increased from $50.1M in FY24, demonstrating investment in innovation.)
- $15.7M — Foreign Currency Impact (Negative impact on revenue, a key risk factor.)
Key Players & Entities
- NEOGEN CORP (company) — filer of 10-K
- IDEXX Laboratories (company) — competitor
- Thermo Fisher Scientific (company) — competitor
- $920.5 million (dollar_amount) — total revenues for fiscal year 2025
- $818.3 million (dollar_amount) — total revenues for fiscal year 2024
- $75.2 million (dollar_amount) — net income for fiscal year 2025
- $12.5 million (dollar_amount) — net loss for fiscal year 2024
- $600.3 million (dollar_amount) — Food Safety segment revenue
- $320.2 million (dollar_amount) — Animal Safety segment revenue
- $15.7 million (dollar_amount) — negative impact from foreign currency fluctuations
FAQ
What were NEOGEN's total revenues for the fiscal year ending May 31, 2025?
NEOGEN's total revenues for the fiscal year ending May 31, 2025, were $920.5 million, an increase from $818.3 million in the previous fiscal year.
Did NEOGEN achieve a net profit or loss in fiscal year 2025?
NEOGEN achieved a net income of $75.2 million in fiscal year 2025, a significant improvement from a net loss of $12.5 million in fiscal year 2024.
What were the key drivers of NEOGEN's revenue growth in fiscal year 2025?
The key drivers of NEOGEN's revenue growth were its Food Safety segment, which generated $600.3 million, and its Animal Safety segment, contributing $320.2 million.
How much did NEOGEN invest in research and development during fiscal year 2025?
NEOGEN invested $55.8 million in research and development during fiscal year 2025, an increase from $50.1 million in the prior year.
What impact did foreign currency fluctuations have on NEOGEN's revenue in fiscal year 2025?
Foreign currency fluctuations had a negative impact of $15.7 million on NEOGEN's revenue in fiscal year 2025.
What is NEOGEN's strategic outlook for future growth?
NEOGEN's strategic outlook focuses on expanding its global market share in food and animal safety diagnostics, leveraging its diversified product offerings and operational efficiencies.
What are the primary risks NEOGEN faces according to the 10-K filing?
Primary risks include foreign currency fluctuations, which impacted revenue by $15.7 million, and ongoing integration challenges from past acquisitions, as well as potential restructuring charges.
How does NEOGEN's performance compare to the previous fiscal year?
NEOGEN's performance significantly improved, swinging from a net loss of $12.5 million in fiscal year 2024 to a net income of $75.2 million in fiscal year 2025, with revenues increasing from $818.3 million to $920.5 million.
What are NEOGEN's main business segments?
NEOGEN's main business segments are Food Safety, which generated $600.3 million in revenue, and Animal Safety, which contributed $320.2 million in revenue.
Why does NEOGEN's 10-K matter for investors?
NEOGEN's 10-K matters for investors because it shows a strong return to profitability with $75.2 million in net income and robust revenue growth to $920.5 million, indicating effective strategic execution and potential for sustained future performance.
Risk Factors
- Foreign Currency Fluctuations [medium — financial]: The company reported a negative impact of $15.7 million on revenue due to foreign currency fluctuations. This risk can affect profitability and the comparability of financial results across different reporting periods.
- Acquisition Integration Challenges [medium — operational]: Ongoing integration challenges from past acquisitions pose an operational risk. Successful integration is crucial for realizing synergies and maintaining operational efficiency.
- Competitive Landscape [medium — market]: The market for food and animal safety diagnostics is competitive. NEOGEN's ability to maintain and expand market share depends on continuous innovation and effective market penetration strategies.
- Evolving Regulatory Environment [low — regulatory]: Changes in food safety and animal health regulations globally could impact product development, market access, and compliance costs. The company must adapt to these evolving standards.
Industry Context
NEOGEN CORP operates in the in vitro and in vivo diagnostic substances industry, specifically focusing on food and animal safety. This sector is characterized by continuous innovation in diagnostic technologies to meet stringent regulatory requirements and evolving market demands for product safety and animal health. The competitive landscape includes both large, diversified healthcare companies and specialized diagnostic providers.
Regulatory Implications
The company must navigate a complex web of global regulations related to food safety and animal health. Compliance with these standards is critical for market access and product approval, and any changes in regulations could necessitate significant adjustments in product development and operational procedures.
What Investors Should Do
- Monitor R&D investment impact
- Assess foreign currency risk management
- Evaluate acquisition integration success
Key Dates
- 2025-05-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, reflecting the company's financial performance and position.
- 2025-07-30: 10-K Filing Date — The official filing date of the annual report, providing investors with comprehensive financial and operational details.
Glossary
- 10-K
- An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (This document provides the detailed financial and operational information for NEOGEN CORP.)
- Food Safety Segment
- The business segment focused on providing diagnostic solutions for detecting contaminants and ensuring the safety of food products. (This segment was a primary driver of NEOGEN's revenue growth in the fiscal year.)
- Animal Safety Segment
- The business segment focused on providing products and services for the health and safety of animals, including diagnostics and pharmaceuticals. (This segment is a significant contributor to NEOGEN's overall revenue.)
- Foreign Currency Fluctuations
- Changes in the exchange rates between different currencies, which can impact the value of a company's revenues and expenses when reported in a single currency. (This factor negatively impacted NEOGEN's revenue by $15.7 million.)
Year-Over-Year Comparison
NEOGEN CORP demonstrated significant financial improvement compared to the prior fiscal year. Total revenue increased by 12.5% from $818.3 million to $920.5 million, and the company swung from a net loss of $12.5 million to a net income of $75.2 million. R&D expenses also saw an increase, indicating a commitment to innovation. However, the company continues to face risks such as foreign currency fluctuations and acquisition integration challenges, which were also present in the previous reporting period.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on July 30, 2025 regarding NEOGEN CORP (NEOG).